(“AJA”) and its subsidiaries. The Transaction, which closed on September 18, 2024, involved the acquisition of AJA’s entire issued and outstanding share capital for a total consideration of $10 million. The Transaction is expected to be accretive to PDH’s earnings per share in the first year following the acquisition.

Sanjeev Parsad, President, CEO and Director of the Company, commented: “I would like to thank the management and board of directors of PDH, AJA Health, ATI and ADI for their hard work since announcing the Transaction last year. It has been an enormous endeavor to finally move forward for these companies and begin to create long-term value for all shareholders. Additional thanks to Maria Nathanail and her team at McLeod Law LLP to ensure all moving parts were aligned and bring the transaction to completion. We will have more information for shareholders in October on the future of the Company.”

Michael Smith, Chairman, and two other members. The new Board of Directors will be responsible for overseeing the company’s operations and strategic direction. Financial Performance The Company’s financial performance is expected to be significantly impacted by the transaction.

The Information Circular provides a comprehensive overview of the Transaction, including the rationale, key terms, and potential impacts on the Company’s stakeholders.

These statements reflect the Company’s beliefs and assumptions and are subject to a variety of risks and uncertainties. The Company undertakes no obligation to update these statements. ## Forward-Looking Statements: A Detailed Exploration

Forward-looking statements are often used in business news releases and financial reports, but their inherent nature poses a significant challenge to investors.

For further information, contact: Sanjeev Parsad, President and CEO Phone: (604) 678.9115 Fax: (604) 678.9279 E-mail: sparsad@pdh-inc.com Web: www.pdh-inc.com